Cargando…

Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2‐Mutant Acute Myeloid Leukemia

Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) proteins catalyze production of the oncometabolite D‐2‐hydroxyglutarate (2‐HG). Ivosidenib and enasidenib are oral inhibitors of mIDH1 and mIDH2, respectively. An open‐label phase 1 study is evaluating the safety and efficacy of ivosidenib or enasidenib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Bin, Chen, Yue, Yin, Feng, Hua, Lei, Almon, Caroline, Nabhan, Salah, Cooper, Michael, Yang, Hua, Hossain, Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303875/ https://www.ncbi.nlm.nih.gov/pubmed/35166065 http://dx.doi.org/10.1002/cpdd.1067

Ejemplares similares

IDH-Mutated AML: Beyond Enasidenib and Ivosidenib Monotherapy: Highlights From SOHO 2021
Publicado: (2022)

Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
por: Fan, Bin, et al.
Publicado: (2019)

Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
por: Jiang, Xuemin, et al.
Publicado: (2021)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
por: Pollyea, Daniel A., et al.
Publicado: (2019)

Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
por: Sumbly, Vikram, et al.
Publicado: (2022)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Myers, Rebecca A., et al.
Publicado: (2018)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
por: Uson Junior, Pedro Luiz Serrano, et al.
Publicado: (2023)

All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
por: Kim, Yundeok, et al.
Publicado: (2020)

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies
por: Fathi, Amir T., et al.
Publicado: (2022)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
por: Vo, Anh Huan, et al.
Publicado: (2022)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
por: Dinardo, Courtney, et al.
Publicado: (2023)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
por: Tejera, Dalissa, et al.
Publicado: (2020)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment
por: Reed, Daniel R, et al.
Publicado: (2019)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
por: de Botton, Stéphane, et al.
Publicado: (2023)

Pharmacokinetics and safety of Enasidenib following single oral doses in Japanese and Caucasian subjects
por: Li, Yan, et al.
Publicado: (2018)

Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2018)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents
por: Khalil, Ahmed F., et al.
Publicado: (2023)

Enasidenib‐induced Sweet syndrome with differentiation syndrome
por: Mohamed, Amr
Publicado: (2021)

Correction to: Ivosidenib: First Global Approval
por: Dhillon, Sohita
Publicado: (2019)

Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
por: Rimini, Margherita, et al.
Publicado: (2023)

Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application
por: Li, Shuang-long, et al.
Publicado: (2020)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy
por: Galkin, Maria, et al.
Publicado: (2019)

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial
por: Zhu, Andrew X., et al.
Publicado: (2021)

Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
por: Tangella, Adarsh Vardhan, et al.
Publicado: (2023)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

UPLC-MS/MS for the Herb-Drug Interactions of Xiao-Ai-Ping Injection on Enasidenib in Rats Based on Pharmacokinetics
por: Wang, Bo-wen, et al.
Publicado: (2021)

Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
por: Stemer, Galia, et al.
Publicado: (2021)

Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome
por: Annamaraju, Pavan, et al.
Publicado: (2020)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rneu2knmjn6tun7t1dilgodv94